

Allens

Deutsche Bank Place
Corner Hunter and Phillip Streets
Sydney NSW 2000 Australia

GPO Box 50
Sydney NSW 2001 Australia

T +61 2 9230 4000
F +61 2 9230 5333
www.allens.com.au

ABN 47 702 595 758



2 July 2024

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000
Australia
By e-lodgement

Dear Sir/Madam

Notice of ceasing to be a substantial holder in Telix Pharmaceuticals Limited (ASX:TLX)

As detailed in the registration statement relating to Telix Pharmaceuticals Limited's (**TLX**) proposed initial public offering in the United States of America (**US**) of American Depositary Shares, Jefferies LLC, Morgan Stanley & Co. LLC, Truist Securities, Inc., William Blair & Company, L.L.C. (together, the **Joint Lead Managers**) and certain director and management shareholders of TLX entered into lock-up agreements in relation to TLX securities. Under the *Corporations Act 2001* (Cth) (**Corporations Act**), entry into these lock-up agreements gave each Joint Lead Manager a 'Relevant Interest' (as defined in the Corporations Act) in the TLX securities that were the subject of the lock-up agreements. These interests were disclosed to the ASX in the form of substantial holder notices lodged on 21 May 2024.

Following TLX's announcement on 14 June 2024 that it had elected to withdraw from the US initial public offering process, the lock-up agreements have terminated, and the Joint Lead Managers have ceased to hold a Relevant Interest in the securities that were the subject of the lock-up agreements. Accordingly, a ceasing to be a substantial holder notice in relation to these interests accompanies this notice.

Yours faithfully

Adrian Amer
Partner
Allens
Adrian.Amer@allens.com.au
T +61 2 9230 4000

Michael Burrell
Senior Associate
Allens
Michael.Burrell@allens.com.au
T +61 2 9230 4000

